X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.
Lead Product(s): Eflornithine
Therapeutic Area: Oncology Product Name: Iwilfin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Product Name: NPJ5008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia and New Zealand. Pedmarqsi is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity induced by cisplatin chemotherapy in patients with localized, non-metastatic solid tumors.
Lead Product(s): Sodium Thiosulfate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Pedmarqsi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Fennec Pharmaceuticals
Deal Size: $271.6 million Upfront Cash: $43.4 million
Deal Type: Licensing Agreement March 18, 2024
Details:
The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.
Lead Product(s): Sodium Chloride,Sodium Bicarbonate,Potassium Chloride
Therapeutic Area: Gastroenterology Product Name: Movicol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs Asset Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 15, 2022
Details:
Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Product Name: PER977
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Covis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.
Lead Product(s): Eflornithine
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: US WorldMeds
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 23, 2021
Details:
Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontrolled bleeding.
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Product Name: PER977
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AMAG Pharmaceuticals
Deal Size: $290.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement July 23, 2020
Details:
Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.
Lead Product(s): Potassium Chloride,Sodium Chloride,Ascorbic Acid
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Faes Farma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
